You need to be logged in to see the full monograph.


Date of issue: October 2016, Version: 2

bumps logo
A corresponding patient information leaflet on USE OF MDMA (ECSTASY) IN PREGNANCY is available.

3,4-methylenedioxymethamphetamine (MDMA) or “ecstasy” is an illicit hallucinogenic amphetamine with strong central nervous system stimulant properties and high abuse potential. MDMA acts to increase the synaptic cleft concentration of catecholamines through inhibition of reuptake.

MDMA is known to act as a vasoconstrictor. Theoretical concerns about increased malformation risk following gestational MDMA exposure are based on the possibility that placental and embryo-fetal perfusion may be compromised during maternal use, thereby increasing the risk of structural anomalies associated with vascular impairment.

The available data concerning fetal outcome following MDMA exposure in pregnancy are limited to two small, uncontrolled prospective case series.  Although an increased overall risk of congenital malformation was suggested in one, the analytical techniques employed are outdated and application of newer methodologies to the data suggest that major malformation rates within this cohort do not significantly exceed those in the general population. Furthermore, no clear malformation pattern was identified and possible confounding as a consequence of underlying maternal illness and concomitant drug use mean that a causal association with MDMA exposure cannot be assumed. One case-control study identified a possible association between use of vasoconstrictive recreational drugs in early pregnancy and increased risk of gastroschisis in the infant; however studies to assess MDMA exposure specifically are required.

Prenatal MDMA exposure has been correlated with poorer motor development in infants up to two years of age. Data regarding other pregnancy and infant outcomes are lacking or too limited to quantify the potential risk that in utero MDMA exposure may pose to the developing fetus.

The need for additional fetal assessment will depend on individual circumstances but should be considered where prolonged or high dose MDMA exposure has occurred.

This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.

If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.

If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.

Disclaimer: Every effort has been made to ensure that this monograph was accurate and up-to-date at the time of writing, however it cannot cover every eventuality and the information providers cannot be held responsible for any adverse outcomes of the measures recommended. The final decision regarding which treatment is used for an individual patient remains the clinical responsibility of the prescriber. This material may be freely reproduced for education and not for profit purposes within the UK National Health Service, however no linking to this website or reproduction by or for commercial organisations is permitted without the express written permission of this service. This document is regularly reviewed and updated. Only use UKTIS monographs downloaded directly from to ensure you are using the most up-to-date version.